NIAID-funded study could offset harsh effects of antibiotics.
Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation. In their study, patients who underwent the procedure were randomly assigned into two groups: one group received standard care and the other received auto-FMT. The researchers found that auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, thus restoring patients’ digestive, immune and other essential functions. With standard care, beneficial bacteria typically take many weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases, including Clostridium difficile.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, provided funding for part of the project. The study report appears in Science Translational Medicine.
“This important study suggests that clinical intervention using auto-FMT can safely reverse the disruptive effects of broad-spectrum antibiotic treatment,” says NIAID Director Anthony S. Fauci, M.D. “If validated in larger studies, this approach may prove to be a relatively simple way to quickly restore a person’s healthy microbiome following intensive antimicrobial therapy.”
Allogenic hematopoietic cell transplantation involves a donor — often but not exclusively a family member — who gives the recipient stem cells that re-establish bone marrow production of blood cells and immune function to combat cancer. Antibiotics are essential to prevent bacterial infections in stem cell recipients. However, antibiotics also destroy beneficial bacteria that enhance immune function and resistance to infection. The loss of beneficial bacteria increases the risk of certain life-threatening infectious diseases and graft-versus-host disease (GVHD).
The study involved cancer patients who provided their own fecal sample, which was frozen and stored prior to their cell transplantation procedure. Weeks later, when physicians confirmed that the transplanted cells were growing, they assessed the status of the patients’ beneficial gut bacteria. The first 25 patients who lacked known beneficial bacteria were enrolled into the study and randomly assigned to the different treatment groups: 14 received auto-FMT by enema and 11 received standard-of-care.
The patients who received auto-FMT consistently regained bacterial diversity, composition and function; recovery of beneficial bacteria in the 11 control patients was delayed.
The researchers are continuing to monitor the study patients to determine if auto-FMT improves patient outcomes, such as the incidence and severity of bacterial, viral and fungal infections and the incidence and severity of GVHD. Whether FMT from a healthy donor would be as beneficial as the patient’s own fecal sample at restoring beneficial bacteria remains to be studied.
Learn more: Fecal microbiota transplantation helps restore beneficial bacteria in cancer patients
The Latest on: Fecal microbiota transplantation
[google_news title=”” keyword=”fecal microbiota transplantation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fecal microbiota transplantation
- Microbiome Alterations Link to Growth Hormone Deficiencyon April 19, 2024 at 4:56 am
Growth hormone deficiency appears to be linked to a particular microbiome signature that could help with the early diagnosis and treatment of short stature, suggest study.
- Researchers conclude fecal transplants can rid patients of resistant gut bacteriaon April 16, 2024 at 12:28 pm
Transferring fecal microbiota from healthy donors to the intestines of chronically ill people has beneficial effects on these recipients' gut bacteria, also in the longer term. This is the conclusion ...
- Rising antibiotic resistance prompts shift to ecological research strategies in infection controlon April 12, 2024 at 5:22 am
The need to enhance research on the interactions between bacterial pathogens and commensals within human microbiomes.
- Examining the Potential of Fecal Transplantation as a Parkinson’s Disease Treatmenton April 8, 2024 at 9:58 pm
Transferring fecal matter between individuals to cultivate a healthy gut microbiota may offer a new approach to alleviate symptoms of Parkinson’s disease. A pioneering clinical trial demonstrated that ...
- Fecal Transplant Improves Symptoms in Early-Stage Parkinson'son April 7, 2024 at 3:28 pm
Fecal microbiota transplantation (FMT) may improve motor symptoms in early-stage Parkinson’s disease (PD). The findings could pave the way for new treatments for PD. The corresponding study was ...
- Belgian breakthrough: Stool transplant shows promise for improving symptoms of Parkinson's diseaseon April 7, 2024 at 5:53 am
“Our results are really encouraging!” said Prof. Arnout Bruggeman, the study’s first author. “After 12, participants who received the healthy donor stool transplant showed a significant improvement in ...
- Stool transplant shows promise for Parkinson's diseaseon April 3, 2024 at 5:00 pm
Now, a groundbreaking clinical study conducted by researchers at Ghent University Hospital, VIB, and Ghent University has demonstrated the potential of fecal microbiota transplantation (FMT ...
- Fecal Microbiota Transplant (FMT) for Irritable Bowel Syndromeon April 1, 2024 at 5:00 pm
Fecal transplants use feces from a donor to help adjust the balance of organisms in your gut. Research is mixed on whether they can help treat IBS, but research is ongoing. Irritable bowel ...
- Researchers Conduct First Fecal Microbiota Transplant in Dolphinson March 24, 2024 at 5:00 pm
Scientists have successfully carried out pioneering fecal microbiota transplantations on Navy bottlenose dolphins that showed signs of gastrointestinal disease. One dolphin in particular who was ...
via Bing News